We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after November 18, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA
BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
Bispecific antibodies against CD3epsilon and BCMA
BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases